## JAZZ: Jazz Pharmaceuticals plc - XLV: Healthcare

### Executive Summary

No thesis match: MRS_20 -2.1% below STRENGTH zone (4.0-10.0%); PEG 3.94 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge. Caution: momentum weakening (-2.5% MRS).

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($156.58)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_20 falling below -5% or breaking key support

### News

- **Articles:** 6
- **Sentiment:** Bullish (Bullish: 1, Bearish: 0)

**1. How Fresh Epidiolex and Ziihera Data Accepted at Key Meetings At Jazz Pharmaceuticals (JAZZ) Has Changed Its Investment Story**
- Source: Simply Wall Street | 20251213T170859 | Somewhat-Bullish | Relevance: 100%
- Jazz Pharmaceuticals announced new data for its epilepsy drug Epidiolex and oncology candidate Ziihera at major medical meetings. This new data strengthens the clinical profile of these growth assets, reinforcing clinician confidence and supporting long-term uptake, although the company still faces headwinds from upcoming patent expirations and high debt. Investors are encouraged to focus on the company's ability to turn recent revenue growth into sustainable profitability.

**2. AQR Arbitrage LLC Sells 9,118 Shares of Jazz Pharmaceuticals PLC $JAZZ**
- Source: MarketBeat | 20251213T090859 | Neutral | Relevance: 100%
- AQR Arbitrage LLC has reduced its stake in Jazz Pharmaceuticals PLC ($JAZZ) by selling 9,118 shares, lowering its total holdings to 81,020 shares valued at approximately $8.6 million. Despite this, several analysts have raised their ratings and price targets for $JAZZ, resulting in a consensus "Moderate Buy" rating with an average price target of $200.47. However, company insiders have been net sellers, offloading 129,291 shares worth $22.7 million in the last 90 days.

**3. Carr Patricia, SVP at Jazz Pharma, sells $797k in JAZZ stock**
- Source: Investing.com | 20251210T100928 | Neutral | Relevance: 100%
- Patricia Carr, SVP and Chief Accounting Officer at Jazz Pharmaceuticals PLC, sold 4,660 shares of JAZZ stock for a total of $797,783. This transaction occurred after the company's stock saw a 51% gain over the past six months, though Carr also exercised options to acquire 4,500 shares. Despite the insider selling, Jazz Pharmaceuticals appears undervalued according to InvestingPro, with analysts revising earnings upward and strong financial metrics like 92% gross profit margins.

**4. Jazz Pharmaceuticals (JAZZ): Valuation Check After Positive Ziihera and Epidiolex Clinical Updates Boost Investor Interest**
- Source: Simply Wall Street | 20251214T230918 | Bullish | Relevance: 100%
- Jazz Pharmaceuticals (JAZZ) has experienced increased investor interest and a significant stock price rally following positive clinical updates for Epidiolex and Ziihera. Despite this rally, the stock still trades nearly 30% below consensus targets, suggesting a potential undervaluation with a fair value estimated at $208.50. Investors are now evaluating whether this presents a timely entry point or if future growth is already factored into its current price.

**5. Mary Elizabeth Henderson Sells 2,238 Shares of Jazz Pharmaceuticals (NASDAQ:JAZZ) Stock**
- Source: MarketBeat | 20251213T000831 | Neutral | Relevance: 100%
- Mary Elizabeth Henderson, SVP of Jazz Pharmaceuticals (NASDAQ:JAZZ), sold 2,238 shares of the company's stock on December 9th, reducing her holding by 10.29%. The transaction was valued at over $379,000, leaving her with 19,508 shares worth approximately $3.31 million. The article also details the company's price performance, institutional holdings, and recent analyst ratings.

### Analyst Activity

**Target Signal:** VERY_BULLISH (Raises: 6, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-10 | Piper Sandler | $219 | $147 | +49% |
| 2025-11-24 | UBS | $188 | $163 | +15% |
| 2025-11-18 | Wells Fargo | $235 | $170 | +38% |
| 2025-11-18 | Baird | $209 | $160 | +31% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-10 | Piper Sandler | reit | Overweight |
| 2025-11-24 | UBS | down | Neutral |
| 2025-11-18 | Wells Fargo | main | Overweight |
| 2025-11-18 | Baird | main | Outperform |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 1 ($0.00M) |
| Sells | 13 ($5.28M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 49.6% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 3 / 6 |

**Top Holders:**
- Vanguard Group Inc: 9.7% (-3.0%)
- Blackrock Inc.: 9.2% (-4.2%)
- JPMORGAN CHASE & CO: 6.2% (+117.0%)
- Dimensional Fund Adv: 4.7% (+11.8%)
- Capital World Invest: 4.2% (+0.4%)

### Key Risks

1. Momentum deterioration: MRS_20 falling (-2.5% 5d) with bearish MACD, trend may be turning.
2. Insider selling cluster: $5.3M in recent transactions.
3. Valuation stretched: PEG 3.9x requires aggressive growth execution.
4. Elevated short interest (9.5%): bears positioning against stock.

### Catalysts

- Analyst target momentum: 6 raises (avg +25%) could attract flows.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

PEG ratio 3.94 signals overvaluation risk, limited margin of safety. Forward P/E 7.4x attractive for 180% earnings growth. Analyst sentiment positive (6 raises, avg +25%). Insider selling cluster ($5.3M in 90 days), potential headwind. Institutional flow bullish (3 buying vs 6 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $10.2B |
| Beta | 0.31 |
| 52W Range | $95.49 - $182.99 |
| Short Interest | 9.5% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 3.94 |
| Forward P/E | 7.4 |
| Current P/E | 20.7 |
| YoY Growth | 180.0% |
| EPS Direction | RISING |

### Technicals

MRS_20 deteriorating from 0.4% to -2.1% (-2.5% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 6.1pp (needs >4.0% for momentum thesis). MRS_5 turning positive (2.5%) - potential reversal signal. Long-term uptrend intact (above SMA200 at 1.33x) but short-term weakness (below SMA20). MACD histogram bearish (-2.00), momentum weakening. RSI neutral at 58. OFD pattern: +MTL (Rally).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | -2.08% (CS: 21) | Weak |
| RSI_14 | 57.7 | Neutral |
| MACD Histogram | -2.00 | Bearish |
| vs SMA20 | 0.984x | Below |
| vs SMA50 | 1.115x | Above |
| vs SMA200 | 1.329x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $167.50
- **Stop Loss:** $156.58 (6.5% risk)
- **Target:** $178.42 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 91
- **Position Value:** $15,242.50
- **Portfolio %:** 15.24%
- **Risk Dollars:** $1,000.00
- **Risk Per Trade:** 1.00%
- **Modifiers:** L1 100% | L2 100% | Combined 1.00x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | NEUTRAL (Zone E) | 1.00x |

*NORMAL regime with moderate risk appetite ahead of Fed decision. VIX remains calm at 15.74 while breadth shows modest participation at 54%, suggesting selective positioning. FOMC meeting in 4 days creates near-term uncertainty but no systemic stress evident.*

### Earnings

**Next:** 2026-02-24 (Est: $6.43)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $5.85 | $8.13 | +39.0% |
| 2025Q2 | $-6.25 | $-8.25 | -32.1% |
| 2025Q1 | $4.66 | $1.68 | -63.9% |
| 2024Q4 | $5.81 | $6.60 | +13.6% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_20*